Company: PBH
Filing Date: 2025-06-27
Form Type: DEF 14A
Source: 0001295947-25-000021
Chunk: 23

Company: Prestige Consumer Healthcare Inc.
Filing Date: 2025-06-27
Form: DEF 14A
Chunk 23
---
 of Directors |     |                                             |     |                            |
| Nominating and CorporateGovernance Committee                                                                                                                                                                                               |     |                    |     | Compensation and TalentManagement Committee |     | Audit and FinanceCommittee |
| Corporate ManagementSocial Responsibility CommitteeSenior Vice President, General Counsel & Corporate Secretary; Vice President, Investor Relations & Treasury;Vice President, Human Resources; Vice President, Manufacturing & Operations |     |                    |     |                                             |     |                            |
| Environmental Health & Safety Manager                                                                                                                                                                                                      |     |                    |     |                                             |     |                            |

Succession Planning Our Board of Directors recognizes that one of its most important duties is to ensure excellence and continuity in our senior leadership by overseeing the development of executive talent and planning for the effective succession of the Chair of our Board of Directors and our CEO and other senior members of executive management. Our CEO and other senior executive succession planning process includes identifying external candidates, where appropriate, and identifying and developing potential internal candidates on an ongoing basis. Our Board of Directors is committed to being prepared for a planned or unplanned change in our leadership in order to ensure our stability. In continuation of this process, the Nominating and Corporate Governance Committee, in collaboration with the Compensation and Talent Management Committee, agree upon and recommend to the Board a succession plan for our CEO in the ordinary course of business and in emergency situations. Through this process, our Board of Directors receives from our CEO qualitative evaluations of, and recommendations concerning, potential successors to our CEO and our other senior executives, along with a review of any development plans recommended for such individuals. At least once annually, our Board of Directors reviews our succession plans. Succession planning is also regularly discussed in executive sessions of our Board of Directors and in committee meetings, as applicable. Our directors become familiar with internal potential successors for key leadership positions through various means, including a comprehensive annual talent and succession review, Board of Directors and committee meeting presentations, and les s formal interactions throughout the course of the year.

| Prestige Consumer Healthcare Inc. | 2025 Proxy Statement |     | 33 |

Our Governance

Director Engagement Meetings and Attendance The Board of Directors held five meetings during fiscal 2025. Each director is expected to attend each meeting of the Board of Directors and those committees on which he or she serves. The Board of Directors expects that its members will attend the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) either in person, by videoconference or by telephone. All our directors attended the 2024 Annual Meeting of Stock